Company intelligence / Profile preview

Mellitus

Boston, Massachusetts, United Statesmedlineplus.gov ↗

Ownership: Private
Development stage: Commercial

Overview

Mellitus developed and commercialized an in vitro diagnostic test for diabetes detection and monitoring. Their main product was a Glycated CD59 (GCD59) enzyme-linked immunosorbent assay that measures GCD59 levels in plasma, providing clinicians with a novel biomarker for diabetes diagnosis and management. The company is now closed.[4]

Therapeutic areas: Endocrinology
Modalities: Diagnostic assay
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Mellitus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mellitus.

Explore the full profile